drugset / Trial / NCT00985933

The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers

NCT00985933

Phase 0 Completed 20 enrolled AstraZeneca
RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this study is to assess if ketamine will induce, in healthy volunteers, impairment of working memory and if the drug AZD8529 will block the effects of ketamine on working memory as assessed by functional magnetic resonance imaging (fMRI).

Timeline

Start
2010-02
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD8529 Other / unclassified 50 mg Oral
Subject AZD8529 Other / unclassified 180 mg Oral

Indications